Celltrion files IND for Humira biosim interchangeability trial in U.S.
이 글자크기로 변경됩니다.
(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.
The global clinical trial is designed to compare treatment outcomes of those who receive Humira and Yuflyma in a crossover fashion and those who maintain Humira treatment to verify the pharmacokinetics, efficacy, and safety of Yuflyma in 366 patients with plaque psoriasis, the Korean company said in a regulatory filing on Monday.
Yuflyma, the world¡¯s first high-concentration adalimumab biosimilar authorized by the European Medicines Agency (EMA), is expected to give more convenience to patients for its reduced dosing. It is also citrate-free, meaning the biosimilar causes less pain after administration compared to Humira.
Celltrion plans to launch Yuflyma in the United States, the world¡¯s largest pharmaceutical market, next year. The interchangeability test, if successful, means the biosimilar¡¯s complete replaceability with its reference drug at pharmacies, thereby enhancing its competitiveness against other Humira biosimilars.
Yuflyma has already received approval for all indications of Humira, including rheumatoid arthritis, inflammatory bowel disease, and psoriasis, and sales have started in major European countries.
Meanwhile, Ildong Pharmaceutical, another Korean pharmaceutical company, announced on Monday it has initiated a Phase 1 study of its investigational nonalcoholic steatohepatitis (NASH) drug codenamed ID119031166M in California.
The company said that the Phase 1 clinical trial protocol okayed by the FDA on July 29 will use a dose escalation scheme to determine the maximum tolerated dose in healthy volunteers. The candidate drug is known to work by regulating the metabolism of bile acids, which are related to fat accumulation, inflammation, and fibrosis in the liver.
[¨Ï Maeil Business Newspaper & mk.co.kr, All rights reserved]
Copyright © 매일경제 & mk.co.kr. 무단 전재, 재배포 및 AI학습 이용 금지
- LG Chem files IND for Phase 3 study of gout drug in U.S. - Pulse by Maeil Business News Korea
- SK geo centric, Tokuyama break ground for wafer cleaning solvent JV in Korea - Pulse by Maeil Business News Korea
- Budget names rapidly exiting from Korean hotel map while luxury category flourishes - Pulse by Maeil Business News Korea
- SK hynix develops DDR5 DRAM CXL memory prototype for mass production in 2023 - Pulse by Maeil Business News Korea
- Use of revolving credit, multiple loans surge in Korea amid rising inflation - Pulse by Maeil Business News Korea
- 강경준, 상간남 피소…사랑꾼 이미지 타격 [MK픽] - 스타투데이
- 고양 덕은·부천 대장…서울은 화곡·가양 [전문가 현장진단]
- 방탄소년단 진, ‘2024 파리 올림픽’ 성화 봉송 주자되다...열일 행보 - MK스포츠
- 이찬원, 이태원 참사에 "노래 못해요" 했다가 봉변 당했다 - 스타투데이
- 양희은·양희경 자매, 오늘(4일) 모친상 - 스타투데이